BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Panther EJ, Lucke-Wold B. Subarachnoid hemorrhage: management considerations for COVID-19. Explor Neuroprotective Ther 2022;2:65-73. [PMID: 35340712 DOI: 10.37349/ent.2022.00018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Hu SQ, Hu JN, Chen RD, Yu JS. A predictive model using risk factor categories for hospital-acquired pneumonia in patients with aneurysmal subarachnoid hemorrhage. Front Neurol 2022;13:1034313. [PMID: 36561302 DOI: 10.3389/fneur.2022.1034313] [Reference Citation Analysis]
2 Yadav D, Song M. Therapeutic Applications of Fucoidans and their Potential to Act Against COVID-19. Curr Pharm Des 2022;28:3671-6. [PMID: 36475344 DOI: 10.2174/1381612829666221207093215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hawsawi Z, Khan D, Fischer I, Cornelius JF, Hänggi D, Muhammad S. SARS-CoV-2 infection increases risk of intracranial hemorrhage. Front Hum Neurosci 2022;16:991382. [PMID: 36504633 DOI: 10.3389/fnhum.2022.991382] [Reference Citation Analysis]
4 Wen L, Zhou L, Wu Q, Zhou X, Zhang X. Feasibility of FDCT Early Brain Parenchymal Blood Volume Maps in Predicting Short-Term Prognosis in Patients With Aneurysmal Subarachnoid Hemorrhage. Front Neurol 2022;13:888369. [DOI: 10.3389/fneur.2022.888369] [Reference Citation Analysis]